463 related articles for article (PubMed ID: 27211601)
1. SUMO5, a Novel Poly-SUMO Isoform, Regulates PML Nuclear Bodies.
Liang YC; Lee CC; Yao YL; Lai CC; Schmitz ML; Yang WM
Sci Rep; 2016 May; 6():26509. PubMed ID: 27211601
[TBL] [Abstract][Full Text] [Related]
2. SUMOylation regulates the number and size of promyelocytic leukemia-nuclear bodies (PML-NBs) and arsenic perturbs SUMO dynamics on PML by insolubilizing PML in THP-1 cells.
Hirano S; Udagawa O
Arch Toxicol; 2022 Feb; 96(2):545-558. PubMed ID: 35001170
[TBL] [Abstract][Full Text] [Related]
3. The promyelocytic leukemia protein isoform PML1 is an oncoprotein and a direct target of the antioxidant sulforaphane (SFN).
Alhazmi N; Pai CP; Albaqami A; Wang H; Zhao X; Chen M; Hu P; Guo S; Starost K; Hajihassani O; Miyagi M; Kao HY
Biochim Biophys Acta Mol Cell Res; 2020 Aug; 1867(8):118707. PubMed ID: 32243901
[TBL] [Abstract][Full Text] [Related]
4. Respiratory syncytial virus induces NRF2 degradation through a promyelocytic leukemia protein - ring finger protein 4 dependent pathway.
Komaravelli N; Ansar M; Garofalo RP; Casola A
Free Radic Biol Med; 2017 Dec; 113():494-504. PubMed ID: 29107745
[TBL] [Abstract][Full Text] [Related]
5. The SUMO2/3 specific E3 ligase ZNF451-1 regulates PML stability.
Koidl S; Eisenhardt N; Fatouros C; Droescher M; Chaugule VK; Pichler A
Int J Biochem Cell Biol; 2016 Oct; 79():478-487. PubMed ID: 27343429
[TBL] [Abstract][Full Text] [Related]
6. Requirement of PML SUMO interacting motif for RNF4- or arsenic trioxide-induced degradation of nuclear PML isoforms.
Maroui MA; Kheddache-Atmane S; El Asmi F; Dianoux L; Aubry M; Chelbi-Alix MK
PLoS One; 2012; 7(9):e44949. PubMed ID: 23028697
[TBL] [Abstract][Full Text] [Related]
7. Site-specific inhibition of the small ubiquitin-like modifier (SUMO)-conjugating enzyme Ubc9 selectively impairs SUMO chain formation.
Wiechmann S; Gärtner A; Kniss A; Stengl A; Behrends C; Rogov VV; Rodriguez MS; Dötsch V; Müller S; Ernst A
J Biol Chem; 2017 Sep; 292(37):15340-15351. PubMed ID: 28784659
[TBL] [Abstract][Full Text] [Related]
8. TGF-β induces PML SUMOylation, degradation and PML nuclear body disruption.
El-Asmi F; El-Mchichi B; Maroui MA; Dianoux L; Chelbi-Alix MK
Cytokine; 2019 Aug; 120():264-272. PubMed ID: 31153006
[TBL] [Abstract][Full Text] [Related]
9. β-catenin inhibits promyelocytic leukemia protein tumor suppressor function in colorectal cancer cells.
Satow R; Shitashige M; Jigami T; Fukami K; Honda K; Kitabayashi I; Yamada T
Gastroenterology; 2012 Mar; 142(3):572-81. PubMed ID: 22155184
[TBL] [Abstract][Full Text] [Related]
10. Small Ubiquitin-like Modifier Alters IFN Response.
Maarifi G; Maroui MA; Dutrieux J; Dianoux L; Nisole S; Chelbi-Alix MK
J Immunol; 2015 Sep; 195(5):2312-24. PubMed ID: 26223657
[TBL] [Abstract][Full Text] [Related]
11. Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3.
Fu C; Ahmed K; Ding H; Ding X; Lan J; Yang Z; Miao Y; Zhu Y; Shi Y; Zhu J; Huang H; Yao X
Oncogene; 2005 Aug; 24(35):5401-13. PubMed ID: 15940266
[TBL] [Abstract][Full Text] [Related]
12. In situ SUMOylation analysis reveals a modulatory role of RanBP2 in the nuclear rim and PML bodies.
Saitoh N; Uchimura Y; Tachibana T; Sugahara S; Saitoh H; Nakao M
Exp Cell Res; 2006 May; 312(8):1418-30. PubMed ID: 16688858
[TBL] [Abstract][Full Text] [Related]
13. Oxidative stress-induced assembly of PML nuclear bodies controls sumoylation of partner proteins.
Sahin U; Ferhi O; Jeanne M; Benhenda S; Berthier C; Jollivet F; Niwa-Kawakita M; Faklaris O; Setterblad N; de Thé H; Lallemand-Breitenbach V
J Cell Biol; 2014 Mar; 204(6):931-45. PubMed ID: 24637324
[TBL] [Abstract][Full Text] [Related]
14. Human Regulatory Protein Ki-1/57 Is a Target of SUMOylation and Affects PML Nuclear Body Formation.
Saito Â; Souza EE; Costa FC; Meirelles GV; Gonçalves KA; Santos MT; Bressan GC; McComb ME; Costello CE; Whelan SA; Kobarg J
J Proteome Res; 2017 Sep; 16(9):3147-3157. PubMed ID: 28695742
[TBL] [Abstract][Full Text] [Related]
15. The Human Cytomegalovirus IE1 Protein Antagonizes PML Nuclear Body-Mediated Intrinsic Immunity via the Inhibition of PML De Novo SUMOylation.
Schilling EM; Scherer M; Reuter N; Schweininger J; Muller YA; Stamminger T
J Virol; 2017 Feb; 91(4):. PubMed ID: 27903803
[TBL] [Abstract][Full Text] [Related]
16. CACUL1/CAC1 attenuates p53 activity through PML post-translational modification.
Fukuda T; Kigoshi-Tansho Y; Naganuma T; Kazaana A; Okajima T; Tsuruta F; Chiba T
Biochem Biophys Res Commun; 2017 Jan; 482(4):863-869. PubMed ID: 27889610
[TBL] [Abstract][Full Text] [Related]
17. NS5 Sumoylation Directs Nuclear Responses That Permit Zika Virus To Persistently Infect Human Brain Microvascular Endothelial Cells.
Conde JN; Schutt WR; Mladinich M; Sohn SY; Hearing P; Mackow ER
J Virol; 2020 Sep; 94(19):. PubMed ID: 32699085
[TBL] [Abstract][Full Text] [Related]
18. An L2 SUMO interacting motif is important for PML localization and infection of human papillomavirus type 16.
Bund T; Spoden GA; Koynov K; Hellmann N; Boukhallouk F; Arnold P; Hinderberger D; Florin L
Cell Microbiol; 2014 Aug; 16(8):1179-200. PubMed ID: 24444361
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies.
Sha Z; Blyszcz T; González-Prieto R; Vertegaal ACO; Goldberg AL
J Biol Chem; 2019 Oct; 294(42):15218-15234. PubMed ID: 31285264
[TBL] [Abstract][Full Text] [Related]
20. C-terminal motifs in promyelocytic leukemia protein isoforms critically regulate PML nuclear body formation.
Li C; Peng Q; Wan X; Sun H; Tang J
J Cell Sci; 2017 Oct; 130(20):3496-3506. PubMed ID: 28851805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
